Literature DB >> 1839793

Simultaneous determination of clarithromycin and 14(R)-hydroxyclarithromycin in plasma and urine using high-performance liquid chromatography with electrochemical detection.

S Y Chu1, L T Sennello, R C Sonders.   

Abstract

A sensitive method for the simultaneous high-performance liquid chromatographic determination of clarithromycin and its active metabolite in plasma and urine is described. Alkalinized samples were coextracted with an internal standard and analyzed on a C8 column using electrochemical detection. Recoveries were greater than or equal to 85% and consistent. Standard curves for plasma were linear in the range 0-2 micrograms/ml for both compounds (r greater than 0.99), with limits of quantification of approximately 10.03 micrograms/ml (0.5-ml sample). Within-day and day-to-day precision were good, with coefficients of variation mostly within +/- 5%; accuracy for both compounds were routinely within 90-110% of theoretical values. Standard curves for urine were linear in the range 0-100 micrograms/ml with limits of quantification of 0.5 micrograms/ml (0.2-ml sample). Urine assays also had similar within-day and day-to-day precisions and accuracy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1839793     DOI: 10.1016/0378-4347(91)80446-j

Source DB:  PubMed          Journal:  J Chromatogr


  22 in total

1.  Pharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patients.

Authors:  D N Fish; E Abraham
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Absolute bioavailability of clarithromycin after oral administration in humans.

Authors:  S Y Chu; R Deaton; J Cavanaugh
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

3.  Efficacy of azithromycin or clarithromycin for prophylaxis of viridans group streptococcus experimental endocarditis.

Authors:  M S Rouse; J M Steckelberg; C M Brandt; R Patel; J M Miro; W R Wilson
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

4.  Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection.

Authors:  M A Polis; S C Piscitelli; S Vogel; F G Witebsky; P S Conville; B Petty; J A Kovacs; R T Davey; R E Walker; J Falloon; J A Metcalf; C Craft; H C Lane; H Masur
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

5.  Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.

Authors:  R Hafner; J Bethel; M Power; B Landry; M Banach; L Mole; H C Standiford; S Follansbee; P Kumar; R Raasch; D Cohn; D Mushatt; G Drusano
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

6.  Clarithromycin increases neuronal excitability in CA3 pyramidal neurons through a reduction in GABAergic signaling.

Authors:  Edyta K Bichler; Courtney C Elder; Paul S García
Journal:  J Neurophysiol       Date:  2016-10-12       Impact factor: 2.714

7.  Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers.

Authors:  K A Rodvold; M H Gotfried; L H Danziger; R J Servi
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

8.  Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration.

Authors:  R A Carr; A Edmonds; H Shi; C S Locke; L E Gustavson; J C Craft; S I Harris; R Palmer
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

9.  Impact of acid secretion, gastritis, and mucus thickness on gastric transfer of antibiotics in rats.

Authors:  P V Sherwood; J I D Wibawa; J C Atherton; N Jordan; D Jenkins; D A Barrett; P N Shaw; R C Spiller
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

10.  Penetration of clarithromycin into lung tissues from patients undergoing lung resection.

Authors:  D N Fish; M H Gotfried; L H Danziger; K A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.